Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Darb Esfahani, Silvia ^a   von Minckwitz, Gunter ^b,c   Denkert, Carsten ^a   Ataseven, Beyhan ^d   Högel, Bernhard ^e   Mehta, Keyur ^b   Kaltenecker, Gabriele ^f   Rüdiger, Thomas ^f   Pfitzner, Berit ^a   Kittel, Kornelia ^g   Fiedler, Bettina ^h   Baumann, Klaus ⁱ   Moll, Roland ⁱ   Dietel, Manfred ^a   Eidtmann, Holger ^j   Thomssen, Christoph ^k   Loibl, Sibylle ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Breast Group C/o GBG Research GmbH   (Germany)

^c University Women's Hospital   (Germany)

^d Department of Gynecology and Obstetrics Rotkreuzklinikum München ^*  (Germany)

^e Instititue of Pathology Rotkreuzklinikum Mu nchen   (Germany)

^f STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^g Krebsheilkunde für Frauen   (Germany)

^h SANA KLINIKUM OFFENBACH   (Germany)

ⁱ UNIVERSITY HOSPITAL MARBURG   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

more..

Author keywords

Apocrine; Breast cancer; CUP; GCDFP 15; Neoadjuvant chemotherapy

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROSS CYSTIC DISEASE FLUID PROTEIN 15; ONCOPROTEIN; UNCLASSIFIED DRUG; ANTHRACYCLINE; AR PROTEIN, HUMAN; BRIDGED COMPOUND; CARRIER PROTEIN; ERBB2 PROTEIN, HUMAN; GLYCOPROTEIN; PIP PROTEIN, HUMAN; TAXANE; TAXOID; ANTHRACYCLINE DERIVATIVE; HORMONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; APOCRINE CARCINOMA; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOPLASM; DISEASE FREE SURVIVAL; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE; TUMOR CELL; TUMOR DIFFERENTIATION; ADJUVANT THERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; METABOLISM; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; APOCRINE GLAND; BREAST BIOPSY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG RESPONSE; GCDFP 15 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST CANCER;

ANTHRACYCLINES; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARRIER PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84904771873     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-546     Document Type: Article

References (28)

1. Haagensen DE, Mazoujian G, Holder WD, Kister SJ, Wells SA. Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg 1977, 185:279-285.
2. Mazoujian G, Pinkus GS, Davis S, Haagensen DE. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983, 110:105-112.
3. Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989, 20:281-287.
4. Loos S, Schulz KD, Hackenberg R. Regulation of GCDFP-15 expression in human mammary cancer cells. Int J Mol Med 1999, 4:135-140.
5. Debily MA, Marhomy SE, Boulanger V, Eveno E, Mariage-Samson R, Camarca A, Auffray C, Piatier-Tonneau D, Imbeaud S. A functional and regulatory network associated with PIP expression in human breast cancer. PLoS One 2009, 4:e4696.
6. Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol 2013, 28:1393-409.
7. Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 2005, 47:195-201.
8. Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, Sakamoto G. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS 2006, 114:712-719.
9. Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol 1986, 123:532-541.
10. Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010, 23:644-653.
11. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671.
12. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008.
13. Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2009, 11:59.
14. von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005, 16:56-63.
15. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008, 100:552-562.
16. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008, 100:542-551.
17. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S. Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. J Clin Oncol 2013, 31:3623-3630.
18. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
20. Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011, 130:477-487.
21. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 2013, 62:267-274.
22. Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, Argani P. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011, 135:587-591.
23. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Vant Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008, 216:141-150.
24. Pagani A, Sapino A, Eusebi V, Bergnolo P, Bussolati G. PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virchows Arch 1994, 425:459-465.
25. Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E, Dietel M, Kristiansen G. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol 2007, 22:1221-1230.
26. Luo MH, Huang YH, Ni YB, Tsang JY, Chan SK, Shao MM, Tse GM. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Hum Pathol 2013, 44:1241-1250.
27. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 1998, 78:360-365.
28. Lakhani S, Ellis IO, Tan PH, van de Vijver MJ. WHO Classification of Tumors of the Breast 2012, Lyon: IARC Press.